Results 71 to 80 of about 4,766 (189)

Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir

Antiviral Therapy
Background Integrase strand transfer inhibitors (INSTIs) have been associated with excess weight gain in people living with HIV compared to other antiretroviral agents. The mechanisms that underlie these effects are not well defined.
Richard Taylor Pickering, Archana Asundi, Alex Olson, Katie Soden, Daniel R Kuritzkes, Nina H Lin   +5 more
doaj   +1 more source

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

BMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee, Joshua P. Havens, Harlan R. Sayles, Jennifer L. O’Neill, Anthony T. Podany, Susan Swindells, Kimberly K. Scarsi, Sara H. Bares   +7 more
doaj   +1 more source

RNA Modifications in Health and Disease

MedComm, Volume 6, Issue 9, September 2025.
Changes in these components profoundly affect the m6A methylation process, leading to a range of physiological and pathological alterations. In recent years, research on the post‐translational modifications of these components has advanced, encompassing ubiquitination, phosphorylation, SUMOylation, O‐GlcNAcylation, and lactylation.
Shiqi Li, Ping Luo, Junli Fan, Yirong Li, Jiancheng Tu, Xinghua Long   +5 more
wiley   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF EMTRICITABINE TENOFOVIR COBICISTAT ELVITEGRAVIR AND ITS COMPARISION WITH A REPORTED METHOD

, 2017
A new stability indicating RP HPLC method has been developed and validated for simultaneous estimation of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir in bulk and dosage forms. The method involves separation on Kromasil C18 column (250mm x 4.6mm
Mangamma.Kuna*, Gowri Sankar Dannana and S.V.U.M.Prasad
core   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, Volume 26, Issue 8, Page 1251-1257, August 2025.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?

, 2017
Ocular toxicity may not only be caused by medication overdoses and drug-drug interactions, but also by the chronic administration of medications at recommended doses.
A. Invernizzi, C. Gervasoni, D. Cattaneo, V. Micheli, A. Riva, RESNATI, CHIARA   +5 more
core   +1 more source

Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register‐based study

HIV Medicine, Volume 26, Issue 8, Page 1311-1316, August 2025.
Abstract Introduction Women remain underrepresented in studies on immunological response (IR) among virally suppressed people living with HIV. Despite receiving antiretroviral therapy (ART) some individuals do not attain an IR, increasing their risk of non‐AIDS morbidity and mortality.
Josefin Nilsson, Olof Elvstam, Erik Sörstedt, Philippe Wagner, Piotr Nowak, Johanna Brännström, Christina Carlander   +6 more
wiley   +1 more source

Susceptibility of HIV-2 integrase variants to raltegravir (RAL) and elvitegravir (EVG).

, 2012
Panels A and C show the EC50 values for wild-type (WT) HIV-2 ROD9 and each of 13 site-directed ROD9 integrase mutants tested against raltegravir and elvitegravir, respectively.
Matthew Coyne (135534), Brad Church (135536), James I. Mullins (30582), Charlotte Pan (135533), Dana N. Raugi (135530), Alexandra Hernandez (135535), Robert A. Smith (135527), Kara Parker (135537), Papa Salif Sow (135540)   +8 more
core   +1 more source

Preparation, Characterization and Evaluation of Elvitegravir-Loaded Solid Lipid Nanoparticles for Enhanced Solubility and Dissolution Rate

, 2015
Purpose: To enhance the aqueous solubility and dissolution rate of elvitegravir (EVG) by formulating the drug as solid lipid nanoparticles (SLNs) using solvent injection method.Methods: EVG-loaded SLNs were prepared by solvent injection method.
Palanisamy, K, Maruthapillai, A, Kommavarapu, P   +2 more
core   +1 more source

Supplementary Data from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m⁶A Methyltransferase METTL3

, 2022
Supplementary Data from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase ...
Zi-Jia Huang (14956611), Guo-Geng Zhang (14956608), Bin Li (14956623), Long Liao (810208), Wei Yu (43094), Shu-Jun Li (9335526), Yan He (116705), Jing Yang (13969), Qing-Yu He (14956617), Can-Can Zheng (14956614), Yan Li (14956620)   +10 more
core   +1 more source